Research and Markets It is Anticipated that by 2010 Sales of Neuropathic Pain Drugs will Double to US$55 Billion

Research and Markets (http://www.researchandmarkets.com/reports/c21934) has announced the addition of CNS Drug Discoveries: Analgesia to their offering.

Focusing on Neuropathic Pain, Pain products generated global sales of nearly US$40 billion in 2004 (including anaesthetics and anti-migraine agents) and this is expected to double by 2010. Pain is associated with a broad range of diseases and is often poorly diagnosed and treated. There has been tremendous research activity into the treatment of pain and many types of pain remain relatively unexplored.

Approximately 26 million patients worldwide (10 million in the US, 3 million in Europe and 1.5 million in Japan) suffer from some form of neuropathic pain , spending an estimated US$2.5 billion globally in 2004. There remains a high unmet clinical need within neuropathic pain as current therapies such as antidepressants are under-utilised and many patients in Europe have inadequate pain management programmes and limited access to opioids.

Global pain market
It is difficult to determine the exact amount spent on the management of pain as several classes of drug are used "off label" in the treatment of pain such as antidepressants and anti-epileptics.

We anticipate that by 2010, sales of neuropathic pain drugs will double to US$5.5 billion. Sales will be driven by the launch of novel therapeutic drugs that specifically target subsets of neuropathic pain associated with: HIV infection, shingles, diabetes, immune disorders and toxic neuropathies (for example following treatment with chemotherapeutics). These include the development of antidepressants (Cymbalta), antiepileptic agents (Lyrica and Prialt) glutamate antagonists (Namenda, Lamictal and CNS 5161) and the cannabinoid agonist (Sativex).

Key questions answered by this chapter include:
What will the value of the pain market be in 2010
What are the clinical and prescribing changes that will encourage growth
What will be the forecast market value and share of the 5 leading products in 2010

What are the prospects for novel drugs such as Neurodex and NGC-2010 that are likely to enter the market from 2007 onwards
What can the industry do to improve the current poor levels of diagnosis

Tables Charts & Figures
Neuropathic market by treatment type 2004.
Forecast of neuropathic pain market by treatment type 2010.
Incidence of different types of pain in the US.
Neuropathic pain population 2003-2010 for US, Europe, Japan and rest of world.

Neurontin drug use by indication.
Discontinued pain treatment drugs.
Drugs in R&D: 45 Phase I-III drugs listed by Phase, developer and class.
Forecast of global drug sales by year to 2010 for antiepileptics, anaethestics, antidepressants and opioids. Specific products: Neurontin and Lidocaine Patch.

SWOT analysis of current therapies.
Forecast global sales by year to 2010 of new drugs such as: - Lyrica (Pfizer) - Lamictal (GSK) - Sativex (Bayer/GW Pharma) - Prialt (Elan) - Namenda (Forest/Lundbeck) - Neurodex (Avanir) - NGX-4010 (NeurogesX) - CNS5161 (CeNeS).
SWOT analysis of notable upcoming products.

For more information visit http://www.researchandmarkets.com/reports/c21934

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980

Research and Markets It is Anticipated that by 2010 Sales of Neuropathic Pain Drugs will Double to US$55 Billion

4016 readers online...

Research and Markets It is Anticipated that by 2010 Sales of Neuropathic Pain Drugs will Double to US$55 Billion

Search